NEW YORK (GenomeWeb) – Australian firm Genome.One and US-based OneOme said today that they have partnered to provide a joint service in Australia to analyze individuals' genetic disease risks and pharmacogenomic-related variants.

As part of the service launched earlier this month, customers will receive genome sequencing provided by Genome.One and pharmacogenomic testing using OneOme's RightMed test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.